Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: Toxicity, pharmacokinetic, and biomarker evaluations

Journal of Clinical Oncology

Volumn 19, Issue 10, 2001, Pages 2754-2763

  Lawrence, Julia A ^b   Adamson, Peter C ^b   Caruso, Rafael ^b   Chow, Catherine ^b   Kleiner, David ^b   Murphy, Robert F ^b   Venzon, David J ^b   Shovlin, Margaret ^b   Noone, Marianne ^b   Merino, Maria ^b   Cowan, Kenneth H ^b   Kaiser, Muriel ^b   O'Shaughnessy, Joyce ^b   Zujewski, JoAnne ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; BIOCHEMICAL MARKER; TAMOXIFEN;

ADULT; AGED; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFECT; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LUNG EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION;

EID: 19244371699     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.10.2754     Document Type: Article

References (64)

1. Ries L, Eisner M, Kosary C, et al: SEER Cancer Statistics Review 1973-1997. Bethesda, MD, National Cancer Institute, 2000
2. American Cancer Society: American Cancer Society Facts and Figures - 1999. Atlanta, GA, American Cancer Society, 1999
3. Rosen P, Groshen S, Saigo P, et al: Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: A study of 644 patients with median follow-up of 18 years. J Clin Oncol 7:1239-1231, 1989
4. Rosen P, Groshen S, Saigo P, et al: A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7:355-366, 1989
5. Buzdar A, Kau S, Smith T, et al: Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol 12:123-128, 1989
6. Buzdar A, Kau S, Hortobagyi G, et al: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69:448-452, 1992
7. Greenberg P, Hortobagyi G, Smith T, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1990
8. Dao T, Nemeto T: Steroid receptors and response to endocrine ablations in women with metastatic cancers of the breast. Cancer 46:2779-2782, 1980
9. Grubbs C, Moon R, Squire R, et al: 13-cis-Retinoic acid: Inhibition of bladder carcinogenesis induced in rats by N-butyl-N-(4-hydroxybutyl)nitrosamine. Science 198:743-744, 1977
10. Moon R, Grubbs C, Spom M, et al: Retinyl acetate inhibits mammary carcinogenesis induced by N-methyl-N-nitrosourea. Nature 267:620-621, 1977
11. Saffiotti U, Montesano R, Sellakumar A, et al: Experimental cancer of the lung: Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20:857-864, 1967
12. Butler W, Fontana J: Responses to retinoic acid of tamoxifen-sensitive and -resistant sublines of human breast cancer cell line MCF-7. Cancer Res 52:6164-6167, 1992
13. Gottardis MM, Lamph W, Shalinsky DR, et al: The efficacy of 9-cis retinoic acid in experimental models of cancer. Breast Cancer Res Treat 38:85-96, 1996
14. Moon R, Kelloff G, Detrisac C, et al: Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res 12:1147-1153, 1992
15. Anzano MA, Byers SW, Smith JM, et al: Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res 54:4614-4617, 1994
16. Bischoff E, Heyman R, Lamph W: Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure. J Natl Cancer Inst 91:2118-2123, 1999
17. Miller VA, Rigas JR, Benedetti FM, et al: Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. Clin Cancer Res 2:471-475, 1996
18. Achkar C, Bentel J, Boylan J, et al: Differences in the pharmacokinetic properties of orally administered all-trans-retinoic acid and 9-cis-retinoic acid in the plasma of nude mice. Drug Metab Dispos 22:451-458, 1994
19. Adamson PC, Murphy RF, Godwin KA, et al: Pharmacokinetics of 9-cis-retinoic acid in the rhesus monkey. Cancer Res 55:482-485, 1995
20. Chambon P: The molecular and genetic dissection of the retinoid signaling pathway. Gene 135:223-228, 1993
21. Chambon P: A decade of molecular biology of retinoic acid receptors. FASEB J 10:940-954, 1996
22. Levin AA, Sturzenbecker LJ, Kazmer S, et al: 9-cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα. Nature 355:359-361, 1992
23. Mangelsdorf D, Borgemeyer U, Heyman R, et al: Characterization of three RXR genes that mediate the action of 9-cis retinoic acid. Genes Dev 6:329-344, 1992
24. Bugge T, Pohl J, Lonnoy O, et al: RXRα, a promiscuous partner of retinoic acid and thyroid hormone receptors. EMBOJ 11:1409-1418, 1992
25. Kliewer SA, Umesono K, Mangelsdorf DJ, et al: Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone, and vitamin D3 signaling. Nature 355:446-449, 1992
26. Gearing K, Gottlicher M, Teboul M, et al: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci U S A 90:1440-1444, 1993
27. Kelloff G, Sigman C, Johnson K, et al: Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9:127-137, 2000
28. Kaiser-Kupfer M, Peck G, Caruso R, et al: Abnormal retinal function with fenretinide, a synthetic retinoid. Arch Ophthalmol 104: 69-70, 1986
29. Kurie JM, Lee JS, Griffin T, et al: Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res 2:287-293, 1996
30. Rizvi NA, Marshall JL, Ness E, et al: Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. Clin Cancer Res 4:1437-1442, 1998
31. Wasserheit C, Oratz R, Downey A, et al: Phase I trial of 9-cis-retinoic acid (LGD-1057, NSC#659772) and tamoxifen in patients with metastatic carcinoma of the breast. Proc Am Soc Clin Oncol 18:695, 1997 (abstr 695)
32. Dhodapkar M, Desikan K, Jagannath S, et al: 9-cis retinoic acid (LGD 1057) therapy results in frequent increase in interleukin-6 (IL-6) bioactivity in multiple myeloma: Results of a phase II trial. Proc Am Soc Clin Oncol 17:87, 1998 (abstr 87)
33. Decensi A, Torrisi R, Polizzi A, et al: Effect of the synthetic retinoid fenretinide on dark adaptation and the ocular surface. J Natl Cancer Inst 86:105-110, 1994
34. Caruso RC, Zujewski J, Iwata F, et al: Effects of fenretinide (4-HPR) on dark adaptation. Arch Ophthalmol 116:759-763, 1998
35. Lewis K, Zech L, Phang J: Effects of chronic administration of N-(4-hydroxyphenyl)retinamide (4-HPR) in rats on vitamin A metabolism in the eye. Eur J Cancer 32A: 1803-1808, 1996
36. Marsden J: Hyperlipidaemia due to isotretinoin and etretinate: Possible mechanisms and consequences. Br J Dermatol 114:401-407, 1986
37. Bershad S, Rubinstein A, Paterniti J, et al: Changes in plasma lipids and lipoproteins during isotretinoin therapy for acne. N Engl J Med 313:981-985, 1985
38. Vahlquist C, Michaelsson G, Vahlquist A, et al: A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins. Br J Dermatol 112:69-76, 1985
39. Cartmel B, Moon TE, Levine N: Effects of long-term intake of retinol on selected clinical and laboratory indexes. Am J Clin Nutr 69:937-943, 1999
40. Omenn G, Goodman G, Thornquist M, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
41. Redlich C, Chung J, Cullen M, et al: Effect of long-term beta-carotene and vitamin A on serum cholesterol and triglyceride levels among participants in the Carotene and Retinol Efficacy Trial. Atherosclerosis 145:425-432, 1999
42. Fisher B, Costantino J, Wickerman D, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
43. Love R, Wiebe D, Newcomb P, et al: Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115:860-864, 1991
44. Grey A, Stapleton J, Evans M, et al: The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 80:3191-3195, 1995
45. Thangaraju M, Kumar K, Gandhirajan R, et al: Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer. Cancer 73:659-663, 1994
46. Conley B, O'Shaughnessy J, Prindiville S, et al: Pilot trial of N-(4-hydroxyphenyl) retinamide (4-HPR, Fenretinide) in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18:275-283, 2001
47. Zujewski J, Pai L, Wakefield L, et al: Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res Treat 57:277-283, 1999
48. Jacobs D, Mebane I, Bangdiwala S, et al: High density lipoproiein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 131:32-47, 1990
49. Castelli W, Anderson K, Wilson P, et al: Lipids and risk of coronary heart disease: The Framingham Study. Ann Epidemiol 2:23-28, 1992
50. Manninen V, Elo M, Frick M, et al: Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 260:641-651, 1988
51. Pittsley R, Yoder FW: Skeletal toxicity associated with long-term administration of 13-cis-retinoic acid for refractory ichthyosis. N Engl J Med 308:1012-1014, 1983
52. DiGiovanna JJ, Helfgott RK, Gerber LH, et al: Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate. N Engl J Med 315:1177-1182, 1986
53. Tangrea JA, Kilcoyne RF, Taylor PR, et al: Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin. Arch Dermatol 128:921-925, 1992
54. DiGiovanna J, Sollitto R, Abangan D, et al: Osteoporosis is a toxic effect of long-term etretinate therapy. Arch Dermatol 131:1263-1267, 1995
55. Okada N, Nomura M, Morimoto S, et al: Bone mineral density of the lumbar spine in psoriatic patients with long term etretinate therapy. J Dermatol 21:308-311, 1994
56. Ruby L, Mital M: Skeletal deformities following chronic hyper-vitaminosis A: A case report. J Bone Joint Surg 56:1283-1287, 1974
57. Means A, Gudas L: The roles of retinoids in vertebrate development. Ann Rev Biochem 64:201-233, 1995
58. Adamson P, Bailey J, Pluda J, et al: Pharmacokinetics of all-trans-retinoic acid administered on an intermittent schedule. J Clin Oncol 13:1238-1241, 1993
59. Muindi J, Frankel SR, Miller WH, et al: Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 79:299-303, 1992
60. Trump D, Smith D, Stiff D, et al: A phase II trial of all-trans-retinoic acid in hormone-refractory prostate cancer: A clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol 39: 349-356, 1997
61. Budd G, Adamson P, Gupta M, et al: Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 4:635-642, 1998
62. Chang J, Powles T, Allred D, et al: Biologic markers as predictors of clinical outcome from systemic therapy of primary operable breast cancer. J Clin Oncol 17:3058-3063, 1999
63. Chang J, Powles T, Allred D, et al: Prediction of clinical outcomes from primary tamoxifen by expression of biologic markers in breast cancer patients. Clin Cancer Res 6:616-621, 2000
64. Clark R, Laidlaw I, Jones L, et al: Effect of tamoxifen on Ki67 labeling index in human breast tumours and its relationship to oestrogen and progesterone receptor status. Br J Cancer 67:606-611, 1993